A groundbreaking study suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC). The findings support the need for clinical trials to determine whether these medications could prevent one of the deadliest types of cancers. Eventually, the medications may also show promise in warding off other types of cancer associated with obesity and diabetes.